Abeona Therapeutics (NASDAQ:ABEO) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a research note released on Monday.

ABEO has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Monday. Oppenheimer started coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Trading Down 0.6 %

ABEO stock opened at $5.12 on Monday. The firm’s fifty day simple moving average is $5.43 and its two-hundred day simple moving average is $5.83. The stock has a market capitalization of $222.57 million, a price-to-earnings ratio of -1.90 and a beta of 1.79. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a twelve month low of $3.05 and a twelve month high of $8.45.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19. As a group, analysts anticipate that Abeona Therapeutics will post -1.16 earnings per share for the current year.

Institutional Trading of Abeona Therapeutics

Large investors have recently modified their holdings of the company. Twinbeech Capital LP purchased a new position in Abeona Therapeutics during the 4th quarter worth $58,000. Squarepoint Ops LLC bought a new position in shares of Abeona Therapeutics during the 4th quarter worth $67,000. Jane Street Group LLC purchased a new position in shares of Abeona Therapeutics during the third quarter valued at $84,000. Oxford Asset Management LLP bought a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $118,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Abeona Therapeutics in the third quarter worth about $151,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.